PUNE, India, June 23, 2016 /PRNewswire/ --

The global chronic lymphocytic leukemia market forecast rise in the development of combination therapies trend is expected to boost market growth. Combination therapies for the treatment of CLL were available only in the form of chemotherapy combination drugs. The approved combinations are chlorambucil in combination with prednisone, and a combination of cyclophosphamide with vincristine and prednisone. However, a growing trend of developing combination therapies to treat CLL has been observed. For instance, TG Therapeutics develops TG-1101 in combination with ibrutinib to treat CLL and MCL. Similarly, the company also develops TG-1101 in combination with TGR-1202 to treat CLL and NHL.

Complete report on industrial chronic lymphocytic leukemia market spread across 78 pages, analyzing 6 major companies and providing 47 data exhibits is now available at http://www.reportsnreports.com/reports/586311-global-chronic-lymphocytic-leukemia-market-2016-2020.html.

The analysts forecast global chronic lymphocytic leukemia market to grow at a CAGR of 19.16% during the period 2016-2020. According to the chronic lymphocytic leukemia market report, a key growth driver is the special regulatory designations offered to certain drugs. Diseases that affect a small percentage of the population, such as CLL, are treated by a few marketed drugs. A small number of patients imply that there is a small market for these drugs, so it may not be profitable for companies to develop these drugs as recovering the R&D expenses would be difficult. To compensate for this limitation and encourage the development of such drugs, regions such as the US and the EU award an Orphan Drug Designation or Breakthrough Therapy Designation to certain drugs.

In the EU, orphan drugs have protocol assistance and 10-year market exclusivity. In the US, this designation translates into incentives such as tax credits for qualified clinical testing, exemptions from prescription drug user fees (unless indicated for additional non-orphan indications), and market exclusivity for seven years. Companies are conducting clinical trials to find the effectiveness of the marketed drugs in all related indications. Drug combinations are also being investigated to increase their effectiveness in treating a particular indication. According to the Surveillance, Epidemiology, and End Results (SEER) factsheets of the National Cancer Institute (NCI) in the US, CLL accounts for one-fourth of all leukemia cases globally.

The research study covers the present scenario and growth prospects of the global chronic lymphocytic leukemia market for 2016-2020. In order to calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The chronic lymphocytic leukemia market report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the generalization of the marketed drugs during the forecast period.

The following companies are the key players in the global chronic lymphocytic leukemia market: F. Hoffman-La Roche, AbbVie, Teva Pharmaceuticals, Gilead Sciences, Johnson & Johnson, and Novartis. Other prominent vendors in the market are: Altor BioScience, Amgen, Arno Therapeutics, AstraZeneca, Bellicum Pharmaceuticals, Biogen, BioLineRx, Boston Biomedical, Celgene, Emergent BioSolutions, Genzyme, iDD biotech, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Karyopharm Therapeutics, Ligand Pharmaceuticals, MedImmune, Merck Sharp & Dohme, Molecular Templates Inc., MorphoSys, Ono Pharmaceutical, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, XEME Biopharma, Xencor, and ZIOPHARM Oncology. Order a copy of Global Industrial Chronic lymphocytic leukemia Market 2016-2020 report @ http://www.reportsnreports.com/Purchase.aspx?name=586311.

Another related report is Global Cancer Immunotherapies Market 2016-2020, the analysts forecast global cancer immunotherapies market to grow at a CAGR of 15.17% during the period 2016-2020. Increased in the demand for cancer monoclonal antibodies will have a big impact on the market. The development and rising demand for cancer monoclonal antibodies have been attributed to the recent understanding of the type of cancer at the molecular level. Browse complete report @ http://www.reportsnreports.com/reports/539145-global-cancer-immunotherapies-market-2016-2020.html.

Explore other new reports on Pharmaceuticals Market @ http://www.reportsnreports.com/market-research/pharmaceuticals/.

About Us:

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:

Ritesh Tiwari

UNIT no 802, Tower no. 7, SEZ

Magarpatta city, Hadapsar

Pune - 411013

Maharashtra, India.

+1 888 391 5441

[email protected]



SOURCE ReportsnReports